JP2005518357A - ベータ３アドレナリンアゴニスト - Google Patents

ベータ３アドレナリンアゴニスト Download PDF

Info

Publication number
JP2005518357A
JP2005518357A JP2003545654A JP2003545654A JP2005518357A JP 2005518357 A JP2005518357 A JP 2005518357A JP 2003545654 A JP2003545654 A JP 2003545654A JP 2003545654 A JP2003545654 A JP 2003545654A JP 2005518357 A JP2005518357 A JP 2005518357A
Authority
JP
Japan
Prior art keywords
formula
mmol
compound
methyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518357A5 (enExample
Inventor
ジョリー・アン・バスティアン
ゲルト・リューター
ダニエル・ジョン・ソール
テオ・ショッテン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2005518357A publication Critical patent/JP2005518357A/ja
Publication of JP2005518357A5 publication Critical patent/JP2005518357A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2003545654A 2001-11-20 2002-11-12 ベータ３アドレナリンアゴニスト Pending JP2005518357A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33403101P 2001-11-20 2001-11-20
PCT/US2002/033625 WO2003044017A1 (en) 2001-11-20 2002-11-12 Beta 3 adrenergic agonists

Publications (2)

Publication Number Publication Date
JP2005518357A true JP2005518357A (ja) 2005-06-23
JP2005518357A5 JP2005518357A5 (enExample) 2006-01-05

Family

ID=23305278

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545654A Pending JP2005518357A (ja) 2001-11-20 2002-11-12 ベータ３アドレナリンアゴニスト

Country Status (8)

Country Link
US (4) US7071208B2 (enExample)
EP (1) EP1448561B1 (enExample)
JP (1) JP2005518357A (enExample)
AT (1) ATE386740T1 (enExample)
AU (1) AU2002353844A1 (enExample)
DE (1) DE60225174T2 (enExample)
ES (1) ES2299618T3 (enExample)
WO (1) WO2003044017A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516211A (ja) * 2003-12-23 2007-06-21 アステラス製薬株式会社 アミノアルコール誘導体

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215028T2 (de) * 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
US7205407B2 (en) * 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
DE60225174T2 (de) * 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
DE102004050952A1 (de) * 2004-10-18 2006-04-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
JP2008100916A (ja) * 2005-01-24 2008-05-01 Dainippon Sumitomo Pharma Co Ltd インドール類およびそれを含む医薬組成物
CA2633536A1 (en) * 2005-12-27 2007-07-05 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1, 5-a]pyridine derivatives
AU2007267183B2 (en) 2006-05-31 2011-10-20 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
ES2369805T3 (es) 2007-06-22 2011-12-07 F. Hoffmann-La Roche Ag Derivados de isoxazol-imidazol.
BRPI0820649A2 (pt) 2007-12-04 2015-06-16 Hoffmann La Roche Derivados de isoxazalo-pirazina
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
JP5466292B2 (ja) 2009-05-05 2014-04-09 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾール−ピリジン誘導体
CN102414208B (zh) 2009-05-05 2014-11-05 霍夫曼-拉罗奇有限公司 作为用于认知性障碍的治疗中的gaba a受体逆激动剂的异*唑-噻唑衍生物
CA2760746C (en) 2009-05-05 2017-07-11 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
US8410104B2 (en) 2009-05-05 2013-04-02 Hoffmann-La Roche Inc. Pyridazines
BRPI1013766A2 (pt) 2009-05-07 2016-04-05 Hoffmann La Roche "derivados de isoxazol-piridina como moduladores de gaba"
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
JP7065951B2 (ja) 2017-09-22 2022-05-12 ジュビラント エピパッド エルエルシー Ｐａｄ阻害剤としての複素環式化合物
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
US20250059184A1 (en) * 2021-12-15 2025-02-20 Delix Therapeutics, Inc. Imidazopyridine psychoplastogens and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624395A5 (enExample) 1976-01-08 1981-07-31 Ciba Geigy Ag
US4314943A (en) * 1977-07-13 1982-02-09 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
CA1116598A (en) 1977-07-13 1982-01-19 William T. Comer 3-indolyl-tertiary butylaminopropanols
JPS6010021B2 (ja) 1979-01-31 1985-03-14 田辺製薬株式会社 新規ベンジルアルコ−ル誘導体及びその製法
DE3423429A1 (de) 1984-06-26 1986-01-02 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4728651A (en) 1985-10-24 1988-03-01 Hoechst-Roussel Pharmaceuticals Inc. Antihypertensive thieno-isoxazoles and -pyrazoles
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
CA2145257A1 (en) 1994-03-23 1995-09-24 Takashi Fujita Thiazolidine and oxazolidine derivatives, their preparation and their medical use
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US6075040A (en) 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
ES2171839T3 (es) 1996-09-05 2002-09-16 Lilly Co Eli Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
BR9807096A (pt) 1997-01-28 2000-04-18 Merck & Co Inc Composto, processos para o tratamento do diabetes, da obesidade em um mamìfero, para reduzir nìveis de triglicerìdeos e nìveis de colesterol ou elevar nìveis de lipoproteìnas de alta densidade, para diminuir a motilidade do intestino, para reduzir inflamação neurogênica das vias aéreas e a depressão e para tratar distúrbios gastrintestinais, e, composições para o tratamento dos distúrbios acima e farmacêutica
US6011048A (en) 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2003055344A (ja) * 1999-01-29 2003-02-26 Dainippon Pharmaceut Co Ltd ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物
WO2001007026A2 (en) 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
WO2001035947A2 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
AU1580001A (en) 1999-11-15 2001-05-30 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
AU2001236471A1 (en) * 2000-01-18 2001-07-31 Neurogen Corporation Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors
WO2002006276A1 (en) 2000-07-13 2002-01-24 Eli Lilly And Company Beta3 adrenergic agonists
CA2421594A1 (en) 2000-11-10 2002-05-16 John Arnold Werner 3-substituted oxindole beta 3 agonists
ES2262817T3 (es) * 2001-08-14 2006-12-01 Eli Lilly And Company Agonistas beta-3 oxindol 3-sustituidos.
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
US7205407B2 (en) * 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
DE60225174T2 (de) 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516211A (ja) * 2003-12-23 2007-06-21 アステラス製薬株式会社 アミノアルコール誘導体

Also Published As

Publication number Publication date
EP1448561B1 (en) 2008-02-20
DE60225174D1 (de) 2008-04-03
DE60225174T2 (de) 2009-02-12
US20060142328A1 (en) 2006-06-29
AU2002353844A1 (en) 2003-06-10
US20060142329A1 (en) 2006-06-29
US7071208B2 (en) 2006-07-04
ATE386740T1 (de) 2008-03-15
EP1448561A1 (en) 2004-08-25
US7241772B2 (en) 2007-07-10
US7265127B2 (en) 2007-09-04
US20060142327A1 (en) 2006-06-29
US20050020618A1 (en) 2005-01-27
WO2003044017A1 (en) 2003-05-30
US7253181B2 (en) 2007-08-07
ES2299618T3 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
JP2005518357A (ja) ベータ３アドレナリンアゴニスト
EP1448560B1 (en) 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS
US6730792B2 (en) β3 adrenergic agonists
US6825220B2 (en) 3-Substituted oxindole β 3 agonists
EP1421078B1 (en) Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes
JP2002513387A (ja) 選択的β▲下３▼アドレナリン作動性アゴニスト
JP2005501856A5 (enExample)
JP2004509873A (ja) セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
KR100248643B1 (ko) 아릴 및 헤테로아릴 알콕시나프탈렌 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050902

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091013